286 related articles for article (PubMed ID: 30452784)
1. Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction-Results of the CHIARA MIA 1 Trial.
Düngen HD; Kober L; Nodari S; Schou M; Otto C; Becka M; Kanefendt F; Winkelmann BR; Gislason G; Richard F; Nielsen OW; Gheorghiade M; Senni M
Clin Pharmacol Drug Dev; 2019 Oct; 8(7):942-951. PubMed ID: 30452784
[TBL] [Abstract][Full Text] [Related]
2. Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction-Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial.
Duengen HD; Kim RJ; Zahger D; Orvin K; Kornowski R; Admon D; Kettner J; Shimony A; Otto C; Becka M; Kanefendt F; Romo AI; Hasin T; Ostadal P; Rojas GC; Senni M;
Am Heart J; 2020 Jun; 224():129-137. PubMed ID: 32375104
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, Safety, and Tolerability of the Novel Chymase Inhibitor BAY 1142524 in Healthy Male Volunteers.
Kanefendt F; Thuß U; Becka M; Boxnick S; Berse M; Schultz A; Otto C
Clin Pharmacol Drug Dev; 2019 May; 8(4):467-479. PubMed ID: 29878583
[TBL] [Abstract][Full Text] [Related]
4. Effects of the chymase inhibitor fulacimstat in diabetic kidney disease-results from the CADA DIA trial.
Rossing P; Strand J; Avogaro A; Becka M; Kanefendt F; Otto C
Nephrol Dial Transplant; 2021 Dec; 36(12):2263-2273. PubMed ID: 33367744
[TBL] [Abstract][Full Text] [Related]
5. Practical algorithms for pharmacologic management of the post myocardial infarction patient.
Reiffel JA; ;
Clin Cardiol; 2005 Nov; 28(11 Suppl 1):I28-37. PubMed ID: 16450810
[TBL] [Abstract][Full Text] [Related]
6. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials.
Fox K; Komajda M; Ford I; Robertson M; Böhm M; Borer JS; Steg PG; Tavazzi L; Tendera M; Ferrari R; Swedberg K
Eur Heart J; 2013 Aug; 34(29):2263-70. PubMed ID: 23536611
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction.
Packer M; Lukas MA; Tenero DM; Baidoo CA; Greenberg BH;
Am J Cardiol; 2006 Oct; 98(7A):39L-45L. PubMed ID: 17023231
[TBL] [Abstract][Full Text] [Related]
8. Indications for immediate angiotensin-converting enzyme inhibition in patients with acute myocardial infarction.
LeJemtel TH; Hochman JS; Sonnenblick EH
J Am Coll Cardiol; 1995 Jun; 25(7 Suppl):47S-51S. PubMed ID: 7775715
[TBL] [Abstract][Full Text] [Related]
9. The long-term impact of the angiotensin-converting enzyme inhibitor trandolapril on mortality and hospital admissions in patients with left ventricular dysfunction after a myocardial infarction: follow-up to 12 years.
Buch P; Rasmussen S; Abildstrom SZ; Køber L; Carlsen J; Torp-Pedersen C;
Eur Heart J; 2005 Jan; 26(2):145-52. PubMed ID: 15618070
[TBL] [Abstract][Full Text] [Related]
10. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
McMurray JJ; Ostergren J; Swedberg K; Granger CB; Held P; Michelson EL; Olofsson B; Yusuf S; Pfeffer MA;
Lancet; 2003 Sep; 362(9386):767-71. PubMed ID: 13678869
[TBL] [Abstract][Full Text] [Related]
11. Effect of ACE inhibitors and angiotensin II type 1 receptor antagonists on endothelial NO synthase knockout mice with heart failure.
Liu YH; Xu J; Yang XP; Yang F; Shesely E; Carretero OA
Hypertension; 2002 Feb; 39(2 Pt 2):375-81. PubMed ID: 11882576
[TBL] [Abstract][Full Text] [Related]
12. Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis.
Xie W; Zheng F; Song X; Zhong B; Yan L
Int J Cardiol; 2016 Feb; 205():65-71. PubMed ID: 26720043
[TBL] [Abstract][Full Text] [Related]
13. Early neurohormonal effects of trandolapril in patients with left ventricular dysfunction and a recent acute myocardial infarction: a double-blind, randomized, placebo-controlled multicentre study.
Sigurdsson A; Eriksson SV; Hall C; Kahan T; Swedberg K
Eur J Heart Fail; 2001 Jan; 3(1):69-78. PubMed ID: 11163738
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-converting enzyme inhibition after myocardial infarction: the Trandolapril Cardiac Evaluation Study.
Torp-Pedersen C; Køber L; Carlsen J
Am Heart J; 1996 Jul; 132(1 Pt 2 Su):235-43. PubMed ID: 8677862
[TBL] [Abstract][Full Text] [Related]
15. Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction.
Weir R; McMurray JJ
Heart; 2005 May; 91 Suppl 2(Suppl 2):ii17-20; discussion ii31, ii43-8. PubMed ID: 15831602
[TBL] [Abstract][Full Text] [Related]
16. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.
Køber L; Torp-Pedersen C; Carlsen JE; Bagger H; Eliasen P; Lyngborg K; Videbaek J; Cole DS; Auclert L; Pauly NC
N Engl J Med; 1995 Dec; 333(25):1670-6. PubMed ID: 7477219
[TBL] [Abstract][Full Text] [Related]
17. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
Pfeffer MA; McMurray JJ; Velazquez EJ; Rouleau JL; Køber L; Maggioni AP; Solomon SD; Swedberg K; Van de Werf F; White H; Leimberger JD; Henis M; Edwards S; Zelenkofske S; Sellers MA; Califf RM;
N Engl J Med; 2003 Nov; 349(20):1893-906. PubMed ID: 14610160
[TBL] [Abstract][Full Text] [Related]
18. Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: The SAVE Study Experience. SAVE Investigators. Survival and Ventricular Enlargement.
Hager WD; Davis BR; Riba A; Moye LA; Wun CC; Rouleau JL; Lamas GA; Pfeffer MA
Am Heart J; 1998 Mar; 135(3):406-13. PubMed ID: 9506325
[TBL] [Abstract][Full Text] [Related]
19. Changes in left ventricular mass and volumes in patients receiving angiotensin-converting enzyme inhibitor therapy for left ventricular dysfunction after Q-wave myocardial infarction.
Foster RE; Johnson DB; Barilla F; Blackwell GG; Orr R; Roney M; Stanley AW; Pohost GM; Dell'Italia LJ
Am Heart J; 1998 Aug; 136(2):269-75. PubMed ID: 9704689
[TBL] [Abstract][Full Text] [Related]
20. Decreasing the Risk of Heart Failure in a Changing Post-Myocardial Infarction Environment.
Rouleau J
N Engl J Med; 2024 Apr; 390(16):1524-1526. PubMed ID: 38587253
[No Abstract] [Full Text] [Related]
[Next] [New Search]
